Abstract
Infections with the fungus Talaromyces (formerly Penicillium) marneffei are rare in patients who do not have AIDS. We report disseminated T. marneffei infection in 4 hematology patients without AIDS who received targeted therapy with monoclonal antibodies against CD20 or kinase inhibitors during the past 2 years. Clinicians should be aware of this emerging complication, especially in patients from disease-endemic regions.
Highlights
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and Emerging Infectious Diseases
We report disseminated T. marneffei infection in 4 hematology patients without AIDS who received targeted therapy with monoclonal antibodies against CD20 or kinase inhibitors during the past 2 years
T. marneffei infection has rarely been seen in non-AIDS patients, even in disease-endemic regions
Summary
Responded to Clearance of T. marneffei antifungal treatment fungemia but died of antifungal treatment antifungal treatment. A serum cryptococcal antigen test result was negative He was empirically given intravenous imipenem/cilastatin and oral doxycycline, but his symptoms persisted. A right cervical lymph node culture yielded T. marneffei His symptoms and radiologic abnormalities resolved after treatment with intravenous amphotericin B for 2 weeks, followed by oral voriconazole for 6 months. Case-Patient 4 Patient 4 was a 67-year-old Chinese man with acute myeloid leukemia and hypertension He had fever and malaise for 2 days without localizing signs. He had been given sorafenib (kinase inhibitor) 8 months earlier for chemotherapy-refractory acute myeloid leukemia (Table 1). His fever did not respond to intravenous meropenem.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
